Success Metrics

Completion Rate
0%(0/1)
Active Trials
0(0%)
Terminated
1(50%)

Phase Distribution

Ph phase_3
1
50%
Ph phase_1
1
50%

Phase Distribution

1

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
Phase 3Large-scale testing
1(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Terminated(2)

Detailed Status

Terminated1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (50.0%)
Phase 31 (50.0%)

Trials by Status

terminated150%
withdrawn150%

Recent Activity

0 active trials
Showing 2 of 2
withdrawnphase_1

Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer

NCT01349088
terminatedphase_3

Study of Motesanib (AMG 706) in Combination With Paclitaxel and Carboplatin for Advanced Non-Squamous Non-Small Cell Lung Cancer

NCT02629848

Clinical Trials (2)

Showing 2 of 2 trials
NCT01349088Phase 1

Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer

Withdrawn
NCT02629848Phase 3

Study of Motesanib (AMG 706) in Combination With Paclitaxel and Carboplatin for Advanced Non-Squamous Non-Small Cell Lung Cancer

Terminated

All 2 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
2